EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSPNAG00000003650
Gene Symbol: TP53
3 Cross references
160 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSPNAG00000000364
Gene Symbol: LOC108412604
3 Cross references
140 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSPNAG00000017526
Gene Symbol: TYR
4 Cross references
198 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSPNAG00000006103
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSPNAG00000010605
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSPNAG00000015507
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSPNAG00000010620
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSPNAG00000027265
Gene Symbol: LOC108412642
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSPNAG00000022232
Gene Symbol: LOC108432264
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSPNAG00000022610
Gene Symbol: LOC108443411
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Fynb-Like

Ensembl ID : ENSPNAG00000024450
Gene Symbol: LOC108415881
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSPNAG00000026593
Gene Symbol: LOC108437224
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).